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Abstract
In recent years, cancer is more and more severe harm to the health of people in the 
world. Although tumour diagnosis and therapy have made some progresses, there is 
little improvement in overall. One of the main reasons is that the pathogenesis of cancer 
metastasis is still enigmatic. Cancer development and metastasis are a complicated pro-
cess that depends on the antigenic properties of cancer cells and a favoured environment 
in organs. Cancer cells metastasis causes more than 90% cancer death in the lungs, liver, 
brain, and bone, and a primary tumour causes less than 10% death. Therefore, under-
standing the process of cancer metastasis is essential, and it is convenient to deal with the 
problem of cancer metastasis and reduce cancer-related thrombosis. It has shown that 
tumour microenvironment plays a significant role in cancer progression. A variety of 
carcinoma-associated fibroblasts, and tumour-related macrophages play expanding and 
critical functions in sustaining cell proliferation, evading growth suppressors, promoting 
survival, activating invasion and metastasis, and reprogramming energy metabolism, 
but the purpose of each constituent remains unknown. This chapter will focus on dis-
cussing the role of the microenvironment on tumour invasion and metastasis to improve 
molecular diagnostics and therapeutics.
Keywords: cancer, metastasis, tumorigenesis, migration, invasion, tumour 
microenvironment, exosomes, autophagy, BMPs
1. Introduction
Cancer cells can be distant metastasis at the late stage, and they can cause damage and injury 
to the body of the patients. Breast cancer is a common clinical malignancy; it can metastasis 
to liver, bone, brain, lung and pleural metastasis, as follows. 1. Metastasis to the liver: Experts 
point out that the rate of breast cancer liver metastasis is 10%, the metastatic pathway has 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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directly reached the liver through blood and lymphatic channel. There was no damage to 
the liver in the early stage. The liver function was normal. Liver volume could be enlarged. 
The condition of the patients deteriorated rapidly and died within a few months in the lat-
ter period. 2. Metastasis to bone: Bone metastases account for secondary blood metastasis 
of breast cancer. Common metastases places are vertebrae, ribs and pelvis. Bone metasta-
ses mainly encroach on the red bone marrow; the X-ray examination shows that it leads 
to irregular bone destruction, similar to the alteration of the insect specimen; some show 
double changes in osteoclast and osteogenesis. 3. Metastasis to brain: Brain metastases are 
rare, accounting for 5% of the metastatic cases of breast cancer, which can be divided into two 
types: meningeal metastasis and brain parenchymal metastasis. Brain metastases can cause 
brain oedema or brain swelling, the symptoms of increased intracranial pressure appear such 
as a headache, vomiting, visual impairment, convulsions and even coma. 4. Metastasis to 
lung and pleural: Lung and pleura are the most common metastatic sites of breast cancer. 
Lung metastases are often nodular and tend to be distributed in the peripheral lung field. The 
principal factors affecting the metastasis of breast cancer are the following factors.
2. Carcinoma-associated fibroblasts (CAFs) in the tumour 
microenvironment
Breast cancer mammary matrix fibroblasts can be regulated by the heat shock protein 1 [heat 
shock factor 1 (HSF1)] and promote the malignancy of a tumour, it indicates that CAFs may 
be activated before epithelial transformation [1]. CAFs are linked to the size of primary breast 
cancer. CAFs are triggered by the paracrine effect of various growth factors, cytokines and 
hormones, which can promote the proliferation of cancer cells. A large number of studies 
have reported that growth factors and their downstream signalling pathways produced by 
CAFs have a role in tumour cell survival, proliferation and cell cycle progression. At the same 
time, tumour cells can induce CAFs to synthesise growth factors and cytokines, and then form 
a positive feedback pathway to encourage tumour development. Studies have confirmed that 
CAFs secreted CXCL12 is linked to breast cancer cell surface homologous receptor CXCR4, 
promoting breast cancer cell growth [2]. HGF derived from CAFs can be bind to the C Met 
receptor and activate downstream signal proteins, such as tyrosine kinase, RAS/RAF/ERK, 
PI3K/AKT, and promote the proliferation of breast cancer cells [3]. In the co-culture of bone 
marrow stomatal cells and breast cancer cells, CAFs phenotype can be obtained, and the 
growth and aggregation of tumour cells are promoted by increasing the ratio of RANKL/OPG 
in breast cancer cells [4]. Besides, CAFs may be a significant source of local oestrogen. Cancer-
associated aromatase can be written in CAFs, resulting in increased oestrogen production and 
tumour cell proliferation [5]. Also, distant metastasis is a significant cause of breast cancer 
death. Metastasis is an ongoing multistage process, including the invasion and growth of 
tumour cells, ECM degradation, tumour cells infiltrating into the blood and lymphatic sys-
tems, and the formation of metastatic clones in distant organs. CAFs activation can affect the 
invasiveness of breast cancer cells. Studies have demonstrated that CAFs can promote the 
invasive phenotype of breast ductal [6].
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3. Tumour-related macrophages (TAMs) in the tumour 
microenvironment
TAMs promote tumour cell proliferation and survival with expression and secretion of a large 
number of factors, such as epidermal growth factor, platelet source growth factor, transform 
growth factor-β1, liver cell growth factor, etc. In vitro, macrophages and tumour cells were co-
cultured, the former can significantly promote the growth of the latter by high secretion of the 
above factors. The tumour cell growth and development were slowed down or even stopped 
mice knock out their macrophages, which confirmed the role of macrophages in promoting 
tumour growth. The results of genetic studies in mice showed that the low rate of tumour 
growth and low metastasis was strictly related to the smaller number of TAMs. The research-
ers established the CSF-1 spontaneous breast cancer mouse model to find tumour prolifera-
tion. Growth rate and lung metastasis rate were lower than those of the wild-type CSF-1 [7].
Three steps can summarise the role of TAMs in tumour invasion and metastasis: The tumour 
cells adhere to the extracellular matrix components to release protein hydrolase to degrade 
extracellular matrix and induce invasion migration with chemokines. The cancer cells are free 
of charge in the primary lesion after proliferation and adhere to the basement membrane. 
The enormous number of matrix proteases released by them will have a destructive effect 
on the extracellular matrix and basement membrane, and then invade the lymphatic vessels 
or blood vessels to cause damage to the tissue and form a metastatic focus. TAMs secrete a 
large number of proteolytic enzymes for tumour invasion and metastasis. For example, matrix 
metalloproteinases, include gelatinase-2, collagen enzyme-1, matrix degradation enzyme-3 
and more than 20 kinds of proteins; these TMMPs enzymes can degrade the extracellular 
matrix and degrade the fibrous collagen. The researchers to establish a breast cancer mouse 
model and find that lung metastasis decreased the loss of systemic macrophages, indicat-
ing that tumour metastasis was affected by TAMs and that macrophages existed in the early 
stages of lesions, invasion and rupture of the basement membrane. And its proteolytic enzyme 
expression is increased (such as Cathepsin B), indicating that TAMs are also engaged when 
tumour cells are in normal tissues around them [8]. Studies have demonstrated that together 
with tumour cells and macrophages, the latter enhances the dynamic properties of the former 
by using the form of MMP and TNF-α [9]. The tissue structure and basement membrane can be 
hit by MMP expression, thus promoting tumour cell growth, diffusion and metastasis. MMP 
in invasive tumours is generally provided by TAMs [10]. TAMs are synergistic with stomatal 
tumour cells and epithelial cells to promote tumour metastasis [11]. The destruction of the 
basement membrane is TAMs, and the proteolytic activity of protease B in the local tissue is 
increased, indicating that TAMs affect the tumour cells to invade the normal tissues around the 
tissue [12, 13]. The study showed that TAMs in different tumour tissues synthesised a series 
of urokinase (urokinase, uPA) involved in tumour invasion, invasion, extracellular matrix 
degradation and tumour angiogenesis [14]. By separating TAMs from breast cancer cells, it 
was found that TGF–beta 1 could stimulate the transcription of uPA in TAMs and enhance the 
stability of uPA Mrna. In addition, TAMs secrete cathepsin to promote tumour development 
by the expression of cathepsin B, cathepsin D and cathepsin L in breast cancer [15].
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4. Exosomes in the tumour microenvironment
The ‘seed’ cells are situated in the primary site of a tumour. They regulate the ‘soil’ micro-
environment of the target organs so that the scattered ‘seed’ cells can adapt to the new ‘soil’ 
and still survive. In the process of the formation of pre-metastatic niche, exosomes play an 
essential role in raising the chemokine receptor, changing the expression of cell adhesion 
molecules and creating an immunosuppressive microenvironment. CHEN and others analyse 
the proteomics in the serum of patients with colon cancer and normal human serum, they 
found that the expression of 36 exosomes proteins in colon cancer patients was up-regulated 
[16]. WANG and others found that a tumour could transfer to the liver by the animal model of 
subcutaneous colon cancer cells HT-29 in nude mice. The exosomes were secreted by HT-29 
cells can collect and express chemokine C-X-C primitives on target organs by CXCR4 [che-
mokine (C-X-C motif) receptor 4, CXCR4] matrix cells to the tumour cells in this process. 
The organisation’s transfer provides favourable conditions [17]. ZHOU and others found that 
miR-105 was carried in the exosomes secreted by breast cancer cells, which can specifically 
lead to the down-regulation of the tight connexin ZO-1 expression in endothelial cells and 
destroy the vascular endothelial barrier, which plays an important role in the early stage of 
microenvironment formation [18].
Exosomes promote the development of inflammatory response and create a pure metastatic 
microenvironment conducive to tumour metastasis. COSTA-SILVA and others found that 
the exosomes derived from pancreatic cancer cells expressed high expression of macro-
phage migration inhibitory factor [macrophage migration inhibitory factor (MIF)], and 
after absorption of these exosomes, the liver macrophages (Kupffer cells) secreted a sig-
nificant amount of TGF beta, and TGF beta promoted the formation of immunosuppres-
sive microenvironment and thus promoted EMT and blood. The TGF beta secreted by liver 
macrophages activates the hepatic stellate cells, up-regulated the expression of fibronectin, 
and then raises bone marrow-derived macrophages in the liver and prepares the microen-
vironment for the arrival of the tumour cells. The exosomes derived from chronic lympho-
cytic leukaemia, carrying protein molecules and miRNA can promote the transformation 
of matrix cells into a tumour-related fibroblasts, release inflammatory response factors, and 
form a microenvironment to tumour growth [19]. The miRNA (miR-21 and miR-29a) car-
ried by the exosomes can combine the Toll-like receptor [Toll-like receptors (TLRs)] of the 
immune cells, resulting in the nuclear factor-kappa B [nuclear factor kappa B (NF-kappa)]. 
The release of tumour necrosis factor–alpha (TNF–a) and IL-6, the activation of the inflam-
matory response factor to encourage the proliferation and metastasis [20, 21]. Exosomes not 
only provides a suitable growth environment for migrating tumour cells but also mediates 
tumour-specific organ metastasis. Hoshino et al. research a variety of exosomes secreted 
by separate metastatic tumour organs [22]. It is found that these exosomes priorities are 
combined with their respective present points of receptor cells. The exosomes mediate the 
tumour’s organ-specific transfer through the exosomes related and activate the Src phos-
phorylation pathway of the receptor cells to up-regulation the gene expression of S100 in 
order to promote the growth of tumour cells [23].
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5. Autophagy associated with cancer metastasis
Autophagy inhibits metastasis of tumour cells by inducing anti-inflammatory effects and lysates 
can cause inflammation in the surrounding tissues, Degenhardt et al. have proved that the 
microenvironment of an inflammatory tumour may lead to invasion and metastasis of tumour 
cells [24]. At the initial stage of primary tumour metastasis, signal stimulation is needed to pro-
mote migration and invasion. Tumour cells get into the systemic circulation through vascular 
infiltration [25]. Hypoxia and oxidative stress usually affect solid tumours, which can lead to cell 
necrosis and inflammatory reaction and inflammatory cells infiltrate. Although some inflam-
matory cells, such as cytotoxic T cells and natural killer cells can antitumour immune responses 
and influence metastasis of tumour. Importantly, inflammatory mediators such as macrophages 
infiltration are often associated with poor clinical prognosis [25–27]. The PyMT (polyoma mid-
dle T) transgenic model of breast cancer metastasis has proved that macrophage infiltration 
in primary tumours is required for invasion and metastasis [28]. Degenhardt and others find 
that autophagy can indirectly inhibit the inflammatory response on the metastatic promoter 
site, by raising the survival rate of tumour cells under hypoxia and metabolic stress [29]. Also, 
autophagy can also regulate the inflammatory response directly by controlling the release of 
immunoregulatory factors such as the release of high mobility group protein 1 [high mobility 
group box protein 1 (HMGB1)]. Once HMGB1 is released, it will activate dendritic cells through 
the Toll-like receptor–4 (Toll-like) of these cells to play a role in inducing cells to produce potent 
antitumour immune responses that kill tumour cells and prevent their metastasis [30]. More 
interestingly, high levels of autophagy could be induced during cell death in malignant glioma 
cells treated with mycin, resulting in a substantial release of HMBG1 from the dead cells [30, 31].
6. Hypoxia-regulated genes implicated in cancer metastasis
The effect of hypoxia on tumour immunity is another essential influence factor. Under the 
condition of hypoxia, tumour cells can secrete a variety of immunosuppressive factors, 
transforming growth factor beta (transforming growth factor-beta) is one of the most critical 
factors. TGF-beta can make tumour cells acquire immune escape function through the fol-
lowing ways: (1) Inhibit the proliferation of cytotoxic T cells and the expression of cytotoxin 
genes, which makes T cells unable to play an antitumour effect and induces the production of 
CD4 + CD25+ regulatory T cells with immunosuppressive function. (2) Inhibit the expression 
of antigen-presenting molecules, conciliatory factors and chemokine receptors to prevent the 
dendritic cells from functioning normally and make dendritic cells unable to deliver tumour 
antigens to T cells [32–35]. (3) Inhibit the activation of natural killer (NK) cells and reduces the 
expression of multiple surface receptors in NK cells so that they cannot identify and dissolve 
tumour cells [36]. In addition, hypoxia can also directly activate myeloid-derived suppressor 
cells (MDSCs), dendritic cells, and programmed cell death receptor ligand 1 [programmed 
cell death-ligand 1 (PD-L1)] through HIF-1 alpha, which can reduce the expression of MDSCs 
secreting interleukin -6 and interleukin -10 p to promote activation in T cells [37–39].
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7. BMPs effect on tumour microenvironment, migration and invasion
BMPs belong to the transforming growth factor-β (TGF-β) superfamily and were initially iden-
tified as obstetrician cytokines that can promote bone and cartilage formation in vivo. Recently, 
BMPs have turned out to be involved in the regulation of tumorigenesis, development and bone 
metastases, they have been shown to be involved in the regulation of tumour development and 
bone metastasis. Clement et al. find BMP2 can enhance the migration and invasion of breast 
cancer cells, those cells with high expression of BMP2 showed more cell migration than GFP 
and blank control group. Katsuno et al. find that BMP2 promotes the invasion and migration 
of MDA-MB-231 through BMPs/SMAD pathway, and the two BMPs receptors play an equally 
important role. Lack of anyone receptor affects the signalling process [40]. BMP2 can promote 
oestrogen receptor positive MCF7 to invade migration in vivo and in vitro [41]. Scherberich 
et al. research show that BMP2 enhances the tumour invasion by regulating the expression of 
skeleton protein M in the tumour microenvironment. BMP2 induces the expression of skeleton 
protein M by p38 MAPK and JNK signalling pathway. BMP2 can also promote the invasion 
and migration of breast cancer by up-regulation the ID1 expression [42]. BMP-4 increases the 
invasion and migration of breast cancer cell by CCN6, which has been shown directly antago-
nise the BMP-4 mediated invasiveness and metastases in vitro and in vivo to. Fibroblasts 
stimulated with BMP-4 enhanced the MCF-7 cell invasion, and these effects were inhibited 
by DMH1. BMP-4 increased the expression of MMP-3 and IL-6 in conditioned medium from 
treated mammary fibroblasts, suggesting BMP-4 can impact the tumour microenvironment to 
promote breast cancer invasion [43]. The latest research has found that BMP6 can inhibit the 
growth and migration of breast cancer cells. Takahashi finds that BMP6 and estradiol co-work 
can inhibit the proliferation of MCF-7 cells through p38 MAPK cell signalling, however, it will 
not play a role only BMP6 exists [24]. Yang et al. also find that BMP6 down-regulates the expres-
sion of miR-192 to inhibit the transcription of ZEB1, and the decrease of miR-21 expression to 
impede the migration ability of MDA-MB-231 and BMP6 could also reduce the proliferation 
ability of MDA-MB-231 cells [25]. Zeisberg et al. find that TGF-beta can reduce the expression 
of E-adhering to renal epithelial cells, but BMP7 can increase the expression of E-adhering. 
Buijs et al. Point out that BMP7 can induce the activity of E-adhering to breast cancer cells 
and reduce invasiveness. Therefore, BMP7 can induce the expression of E-adhering in normal 
epithelial cells and maintain the stability of epithelial cells, loss of BMP7 gene will decrease of 
the expression of E- adhering to lead the epithelial cells to the stomatal cells in the evolution of 
the tumour [44]. Alamo finds that BMP7 stimulates the growth of two breast cancer cell lines 
and inhibits the proliferation of four breast cancer cell lines. Exogenous BMP7 can significantly 
enhance the migration of MDA-MB-231 in vitro. The causes of these two differences are not yet 
clear, Ye Lin has found that the expression of BMP10 in breast cancer is reduced. It can inhibit 
the invasion and migration of MDA-MB-231 through the BMPs/SMAD pathway and suggests 
that BMP10 can serve as a target for molecular therapy of breast cancer [45].
8. BMPs and bone metastasis
There are comparatively few studies on the role of BMPs in bone metastasis of breast can-
cer. Recently, it has been noted that BMPs is involved in the process of breast cancer bone 
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metastasis. BMP has been involved in the development of bone metastases in up-regulating or 
down-regulating the corresponding regulatory factors in breast cancer cells. BMPs can increase 
the expression of Osteoblast bone saliva protein BSP. BSP is related to the formation of new 
bone, so it can connect to the process of breast cancer with bone metastasis. Runx2 similar to 
BSP is that the target gene of BMP, which is closely linked to the osteolytic metastasis of breast 
cancer [46].
The overexpression of BMP7 or exogenous BMP7 can significantly reduce the forma-
tion of bone metastasis by reducing the expression of romantic, increasing the expression of 
E-cadherin and reversing the EMT in the animal model of mouse breast cancer bone metas-
tases. In contrast, additional studies found BMPs could increase the invasion of a tumour 
and the ability of bone metastases and the active SMAD1/5/8 was detected in primary and 
metastatic tumours [47].
In conclusion, BMPs involves the growth and invasion of breast cancer. Different types of 
BMPs have different roles in the same breast cancer cell line, even if the same kind of BMPs 
has different effects on various breast cancer cell lines. It is believed that this mechanism 
will be clarified with the research. BMP9 can inhibit the growth of breast cancer cells in vitro 
and in vivo, BMP-9 is also involved in the inhibition of tumour growth in bone by down-
regulation of connective tissue growth factor(CTGF).
9. Conclusions
It has shown that tumour microenvironment plays an essential role in cancer progression. The 
more recent studies have demonstrated hypoxic and autophagy in both primary tumours and 
metastases, contributing to angiogenesis, invasion, BMPs can inhibit or promote the growth 
of breast cancer by different signalling pathway. It detects a promising therapeutic value for 
BMPs in the management of metastases by influencing the propensity to disseminate to and 
survive in the bone microenvironment.
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